<DOC>
	<DOCNO>NCT01156779</DOCNO>
	<brief_summary>This Phase I clinical study evaluate safety tolerance DA-3091 characterize pharmacokinetic/pharmacodynamic DA-3091 healthy male subject</brief_summary>
	<brief_title>Study Evaluate Safety PK/PD DA-3091 Healthy Male Subjects</brief_title>
	<detailed_description>This phase I dose escalation study . To meet clinical objective , use two-part approach . In part I , 4 subject inject 0.5mg dose DA-3091 placebo ( Single/Subcutaneous Injection ) . After completion part I study , report data safety IDMC . In part II , 8 subject per group inject 1mg , 2mg , 4mg DA-3091 placebo dose escalate protocol . The ratio DA-3091 placebo 3:1 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>1 . Age : 20 ~ 45 year old 2 . Healthy Male 3 . Body weight : ≥50kg Ideal body weight ± 20 % 4 . Informed consent 1 . Clinically significant medical history 2 . Acute Chronic pancreatitis 3 . Clinically significant hypersensitivity Drugs 4 . Clinically significant cutaneous disorder 5 . History administration exenatide 6 . Disorder blood pressure 7 . History drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>SR-Exenatide</keyword>
</DOC>